A 68-year-old woman with diabetes and hypertension undergoes epidural anesthesia for hip arthroplasty. The anesthesiologist injects 18 mL of 2% lidocaine with 1:200,000 epinephrine at L2–L3. After 20 minutes, the patient develops tinnitus, perioral numbness, and tremor. Blood pressure is 165/98 mmHg, heart rate 128/min, and the patient is anxious. What is the most appropriate immediate management?

Explanation

## Recognition of Local Anesthetic Systemic Toxicity (LAST) The clinical presentation—tinnitus, perioral numbness, tremor, hypertension, and tachycardia—is classic for **local anesthetic systemic toxicity (LAST)**, specifically the **CNS phase** preceding cardiovascular collapse. The patient received 360 mg of lidocaine, which exceeds the safe dose (4.5 mg/kg = ~300 mg for a 70 kg patient), especially with the addition of epinephrine. **High-Yield:** LAST occurs when local anesthetic enters the systemic circulation (intravascular injection, overdose, or rapid absorption). Early signs are CNS excitation; late signs are CNS depression and cardiovascular collapse. ## Phases of Local Anesthetic Toxicity | Phase | CNS Signs | Cardiovascular Signs | Mechanism | |-------|-----------|----------------------|----------| | **Early (Excitation)** | Tinnitus, perioral numbness, tremor, agitation | Hypertension, tachycardia | Inhibition of inhibitory pathways | | **Late (Depression)** | Seizures, loss of consciousness, apnea | Hypotension, bradycardia, arrhythmias, cardiac arrest | Global CNS depression + myocardial depression | ## Lipid Emulsion Therapy: The Gold Standard **Key Point:** Intravenous lipid emulsion (20% Intralipid) is the definitive treatment for LAST. It works by: 1. **Sequestration:** Lipid droplets trap lipophilic local anesthetic molecules, reducing free plasma concentration 2. **Redistribution:** Shifts drug away from CNS and myocardium 3. **Metabolic support:** Provides energy substrate to the myocardium during resuscitation **Dosing Protocol:** - **Bolus:** 1.5 mL/kg IV over 1 minute (e.g., 105 mL for 70 kg patient) - **Infusion:** 0.25 mL/kg/min after bolus - **Repeat bolus:** Every 5–10 minutes if seizures or cardiovascular instability persists (max 10–12 mL/kg in first 30 minutes) ```mermaid flowchart TD A[Suspected LAST]:::urgent --> B[Stop injection, call for help]:::action B --> C[Establish IV access, apply monitors]:::action C --> D[Lipid emulsion 1.5 mL/kg IV bolus]:::action D --> E[Start lipid infusion 0.25 mL/kg/min]:::action E --> F{Seizure or CV instability?}:::decision F -->|Yes| G[Repeat bolus q5-10 min, max 10-12 mL/kg/30 min]:::action F -->|No| H[Continue infusion, monitor closely]:::action G --> I[Airway management if needed]:::action I --> J[ICU admission for monitoring]:::outcome ``` **Clinical Pearl:** Lipid emulsion is superior to other interventions (seizure prophylaxis, vasopressors, antiarrhythmics) because it addresses the root cause—removal of local anesthetic from the CNS and myocardium. It should be given immediately upon suspicion of LAST, not after confirmation. **Mnemonic:** **LAST Lipid Protocol = LIP** - **L** = Lipid emulsion first - **I** = IV access and infusion - **P** = Persistent monitoring and repeat dosing ## Why Other Options Are Suboptimal **Warning:** Diazepam (option B) is a temporizing measure only—it treats seizures symptomatically but does NOT remove the offending drug. Sodium bicarbonate (option D) has no role in LAST management. Lumbar puncture (option C) is contraindicated in acute toxicity and delays definitive treatment.